GRACE FORD: Open Payments
NPI 1376815134 · POPLARVILLE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,015 in 45 payments from 12 companies in 2025. Trend: 2023 $539 · 2024 $868 · 2025 $1,015
Food & beverage: $1,015
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. | 8 | $201 |
| Regeneron Healthcare Solutions, Inc. | 9 | $173 |
| AstraZeneca Pharmaceuticals LP | 3 | $162 |
| Novartis Pharmaceuticals Corporation | 5 | $114 |
| Lilly USA, LLC | 5 | $82 |
| ABBVIE INC. | 4 | $64 |
| Amgen Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Novo Nordisk Inc | 2 | $35 |
| Astellas Pharma US Inc | 1 | $35 |
Products named: Xolair, DUPIXENT, BREZTRI, MOUNJARO, VRAYLAR, Rhapsido, TAKHZYRO, FARXIGA.
Industry payments across MS — which companies pay providers there.
